Allogene Therapeutics (ALLO) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$2.0 billion.
- Allogene Therapeutics' Retained Earnings fell 1204.61% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 1204.61%. This contributed to the annual value of -$1.8 billion for FY2024, which is 1648.86% down from last year.
- Allogene Therapeutics' Retained Earnings amounted to -$2.0 billion in Q3 2025, which was down 1204.61% from -$1.9 billion recorded in Q2 2025.
- Allogene Therapeutics' Retained Earnings' 5-year high stood at -$679.4 million during Q1 2021, with a 5-year trough of -$2.0 billion in Q3 2025.
- Its 5-year average for Retained Earnings is -$1.4 billion, with a median of -$1.4 billion in 2023.
- Per our database at Business Quant, Allogene Therapeutics' Retained Earnings crashed by 5077.61% in 2021 and then crashed by 1204.61% in 2025.
- Allogene Therapeutics' Retained Earnings (Quarter) stood at -$894.6 million in 2021, then plummeted by 38.05% to -$1.2 billion in 2022, then dropped by 26.5% to -$1.6 billion in 2023, then dropped by 16.49% to -$1.8 billion in 2024, then fell by 8.36% to -$2.0 billion in 2025.
- Its Retained Earnings stands at -$2.0 billion for Q3 2025, versus -$1.9 billion for Q2 2025 and -$1.9 billion for Q1 2025.